Key Points
- Director Barbara Weber sold 30,519 shares on Feb. 3 at an average price of $12.26 for proceeds of $374,162.94, leaving her with 1,629,254 shares (a 1.84% reduction) valued at about $19.97 million.
- Tango Therapeutics (NASDAQ:TNGX) trades around $12.32 with a $1.66 billion market cap and an analyst consensus of Moderate Buy (target $13.60) after a recent quarter that beat EPS estimates ($0.13 vs. $0.01) despite negative net margins.
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) CFO Daniella Beckman sold 10,317 shares of the business's stock in a transaction dated Tuesday, February 3rd. The stock was sold at an average price of $12.26, for a total value of $126,486.42. Following the transaction, the chief financial officer directly owned 184,297 shares of the company's stock, valued at $2,259,481.22. This represents a 5.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Tango Therapeutics Trading Down 1.8%
Shares of TNGX stock opened at $12.32 on Thursday. The firm has a market capitalization of $1.66 billion, a P/E ratio of -13.25 and a beta of 1.75. Tango Therapeutics, Inc. has a 1 year low of $1.03 and a 1 year high of $13.46. The firm's fifty day simple moving average is $10.34 and its 200 day simple moving average is $8.52.
Tango Therapeutics (NASDAQ:TNGX - Get Free Report) last posted its quarterly earnings results on Tuesday, November 4th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.01 by $0.12. The firm had revenue of $53.81 million during the quarter, compared to analysts' expectations of $41.35 million. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%. Equities research analysts anticipate that Tango Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Several research analysts recently issued reports on TNGX shares. Weiss Ratings reissued a "sell (e+)" rating on shares of Tango Therapeutics in a research report on Wednesday, January 21st. Wolfe Research initiated coverage on Tango Therapeutics in a research note on Tuesday, November 18th. They issued a "peer perform" rating on the stock. Wall Street Zen raised Tango Therapeutics from a "hold" rating to a "buy" rating in a report on Saturday, December 13th. Piper Sandler boosted their price target on Tango Therapeutics from $11.00 to $14.00 and gave the company an "overweight" rating in a research note on Friday, January 16th. Finally, B. Riley upped their price target on Tango Therapeutics from $8.00 to $14.00 and gave the company a "buy" rating in a research report on Tuesday, November 18th. Six analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $13.60.
Check Out Our Latest Report on Tango Therapeutics
Institutional Trading of Tango Therapeutics
Several large investors have recently made changes to their positions in the business. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in shares of Tango Therapeutics by 148,800.0% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company's stock valued at $40,000 after buying an additional 4,464 shares in the last quarter. CWM LLC grew its holdings in Tango Therapeutics by 182.2% during the 2nd quarter. CWM LLC now owns 4,905 shares of the company's stock worth $25,000 after acquiring an additional 3,167 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company's stock valued at $58,000 after acquiring an additional 2,243 shares in the last quarter. Legal & General Group Plc increased its holdings in shares of Tango Therapeutics by 30.7% in the second quarter. Legal & General Group Plc now owns 6,985 shares of the company's stock valued at $36,000 after purchasing an additional 1,640 shares in the last quarter. Finally, Russell Investments Group Ltd. increased its stake in shares of Tango Therapeutics by 461.3% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,729 shares of the company's stock valued at $65,000 after buying an additional 6,352 shares during the period. Institutional investors own 78.99% of the company's stock.
About Tango Therapeutics
(
Get Free Report)
Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company's lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
